S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
Teva Pharma is the way to play the re-rise of generic drugs

Chris Growe - Analyst Performance

This page shows the methodology used to calculate Stifel Nicolaus analyst Chris Growe's recommendation performance. Listed below are links to the research notes issued, the price targets issued by the analyst, and the stock's actual price 12 months from the date the research note was issued. These rankings are based on research reports from 11/28/2018 and 11/28/2022. Rankings are updated daily.

Average 12-Month ROI of Buy and Strong Buy Recommendations: ???%

MarketBeat Analyst Ranking: starstarxxx
Export to Excel
CompanyReport DateReport Date Price12-Month
Price Target		Rating12-Month
Actual Price		12-Month
ROI		Details

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Upgrade Now See Benefits

Already have an account? Log in here.



How are MarketBeat's Analyst Rankings Calculated? MarketBeat uses the average return on investment of an analyst's "buy" and "strong buy" recommendations over the last five years to determine their star rating. The firms with the best-performing recommendations receive a five-star rating. Analysts that have issued fewer than five tracked research notes in the last five years will not be ranked.

Return to Analyst Rankings

My Account -